An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: Reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis

Purpose: To compare emedastine ophthalmic solution 0.05% BID to levocabasti ne ophthalmic suspension 0.05% BID in reducing chemosis, eyelid swelling an d other signs and symptoms in subjects with seasonal allergic conjunctiviti s. Methods: In a randomized, double-masked, parallel controlled study, emedast ine ophthalmic solution 0.05% BID was compared to levocabastine ophthalmic suspension 0.05% BID for control of chemosis, eyelid swelling and other par ameters in the environmental allergy study model. Results: At Days 7, 14, 30 and 42, emedastine was significantly better than levocabastine at controlling chemosis and eyelid swelling (p<0.05), A stat istical trend was seen at Day 3 (0.05<p<0.10), Results were clinically rele vant at Days 30 and 42, Emedastine was also significantly better at reducin g redness and itching at Days 7, 14, 30 and 42 (p<0.05), Conclusion: Emedastine is more efficacious than levocabastine in reducing c hemosis, eyelid swelling and other efficacy variables associated with seaso nal allergic conjunctivitis.